<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150420</url>
  </required_header>
  <id_info>
    <org_study_id>ST-001</org_study_id>
    <nct_id>NCT03150420</nct_id>
  </id_info>
  <brief_title>A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients</brief_title>
  <acronym>CALISTA</acronym>
  <official_title>A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hope Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate
      the efficacy and safety of intravenous Sodium Thiosulfate Injection for treatment of acute
      calciphylaxis-associated pain in chronic hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial will
      evaluate the efficacy and safety of intravenous Sodium Thiosulfate Injection for treatment of
      acute calciphylaxis-associated pain in chronic hemodialysis patients. Acute calciphylaxis-
      associated pain intensity will be the primary outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with 30% improvement in pain severity</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>To compare the effects of treatment with intravenous Sodium Thiosulfate Injection vs. placebo for the proportion of patients (responders) who achieve a ≥ 30% reduction based upon pain intensity score (modified BPI/SF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-a: Number of patients with stabilization or improvement in calciphylaxis skin lesions.</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>Proportion of patients who achieve improvement or stabilization (i.e., not worsening) of skin lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-b: Occurence of surgical debridement of skin lesions and/or amputation.</measure>
    <time_frame>during week 3</time_frame>
    <description>Occurence of surgical debridement of skin lesions and/or amputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-c: Occurrence of surgical debridement of skin lesions and/or amputation.</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>Occurrence of surgical debridement of skin lesions and/or amputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-d: Time to achieve ≥ 30% improvement in pain severity</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>Time in days when a patient achieves a ≥ 30% improvement based upon pain intensity score (modified BPI/SF).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Calciphylaxis</condition>
  <arm_group>
    <arm_group_label>Sodium Thiosulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Thiosulfate Injection (25 grams sodium thiosulfate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride injection, USP (normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks</description>
    <arm_group_label>Sodium Thiosulfate</arm_group_label>
    <other_name>Intravenous Sodium Thiosulfate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Normal Saline</intervention_name>
    <description>Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks</description>
    <arm_group_label>Placebo-Normal Saline</arm_group_label>
    <other_name>0.9% sodium chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed of the investigational nature of the study and sign written informed consent

          -  Willing and able to adhere to all study-related procedures, including adherence to
             study medication regimen

          -  Male or female ≥18 years old

          -  End-stage renal disease on chronic hemodialysis

          -  Calciphylaxis with active skin lesion(s) of any morphological appearance (including
             but not limited to livedo, induration, ulceration, etc.) and tissue histology review
             consistent with calciphylaxis diagnosis. Histological features consistent with
             calciphylaxis will include soft tissue calcification, microthrombosis, and/or
             fibrointimal hyperplasia of dermal arterioles

          -  Acute pain associated with calciphylaxis lesions pain intensity score of ≥ 5 at
             initial screening on the modified BPI/SF scale

          -  Women of childbearing potential must have a pregnancy test (urine or serum [if
             anuric]) at screening and not be pregnant and willing to use an acceptable method of
             contraception for the entire duration of the study (3 weeks)

        Exclusion Criteria:

          -  Peritoneal dialysis patients

          -  Current congestive heart failure exacerbation

          -  Baseline abnormalities related to QT prolongation (corrected QT interval &gt; 470 ms),
             hypocalcemia (serum albumin-corrected calcium &lt; 8 mg/dL ), metabolic acidosis (serum
             bicarbonate &lt; 18 mmol/L, hypotension (resting systolic blood pressure while seated &lt;
             80), or interdialytic weight gain ≥ 4.0 kg

          -  History of ventricular arrhythmias including ventricular fibrillation or ventricular
             tachycardia associated with shortness of breath, dizziness, hypotension, or syncope

          -  Any prior (within the past 30 days) or current intravenous Sodium Thiosulfate
             Injection treatment

          -  Other investigational agent (drug, biologic, or device) study within the past 30 days
             and/or for the duration of the trial

          -  Pregnant or lactating women

          -  History of allergy to sulfites, thiosulfate, or any component in Sodium Thiosulfate
             Injection (sulfa allergy is not an exclusion criterion)

          -  Significant other acute or chronic concomitant diseases (including but not limited to
             hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema,
             pulmonary embolism) that would be inconsistent with survival for at least 3 months

          -  Other serious concurrent or recent medical or psychiatric condition which, in the
             opinion of the Investigator, makes the patient unsuitable for participation in this
             study

          -  Ongoing application of dialysate admixed with iron salt e.g. ferric pyrophosphate
             during the entire trial period (patients who are on dialysate admixed with iron salt
             at screening are eligible if dialysate admixed with iron salt can be substituted with
             non-iron based dialysate and patients can be maintained on non-iron based dialysate
             therapy for the entire duration of trial period)

          -  Recent (within 1 week) history of surgical parathyroidectomy or scheduled for surgical
             parathyroidectomy during the course of the study

          -  History of opioid addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Sherman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hope Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Sherman, MD</last_name>
    <phone>480-607-1970</phone>
    <email>sherman@hopepharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Tuazon, MD</last_name>
      <phone>312-503-1887</phone>
      <email>jtuazon@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Fox</last_name>
      <phone>312-503-1887</phone>
      <email>patrick.fox@northwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinod Bansal, MD</last_name>
      <phone>708-216-3306</phone>
      <email>vbansal@lumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sana Iqbal</last_name>
      <phone>708-216-3268</phone>
      <email>siqbal5@luc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lama Noureddine, MD</last_name>
      <phone>319-356-4409</phone>
      <email>lama-noureddine@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ann Rhomberg</last_name>
      <phone>319-356-0575</phone>
      <email>ann-rhomberg@uiowa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagar Nigwekar, MD</last_name>
      <phone>617-726-7872</phone>
      <email>sagarnigs@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Laurence Mercier-Lafond</last_name>
      <phone>(857) 294-3714</phone>
      <email>lmercier-lafond@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Gosmanova, MD</last_name>
      <phone>518-626-6463</phone>
      <email>Elvira.Gosmanova@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Elissa Ball</last_name>
      <phone>518-626-6447</phone>
      <email>elissa.ball@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Heyka, MD</last_name>
      <phone>216-444-8896</phone>
      <email>heykar@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Dianna Sendry, RN</last_name>
      <phone>216-444-0486</phone>
      <email>sendred2@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devamita Dev, MD</last_name>
      <phone>540-982-2463</phone>
      <phone_ext>2444</phone_ext>
      <email>devasmita.dev@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Leslie McNeil</last_name>
      <phone>540-982-2463</phone>
      <phone_ext>4663</phone_ext>
      <email>lesley.mcneil@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Calgary Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2W 1S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer MacRae, MD</last_name>
      <phone>403-944-2566</phone>
      <email>jmmacrae@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sheilah Heal, RN</last_name>
      <phone>403-955-6385</phone>
      <email>heal@ucalgary.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calciphylaxis</keyword>
  <keyword>calcific uremic arteriolopathy, calcinosis</keyword>
  <keyword>calcium metabolism disorders</keyword>
  <keyword>metabolic diseases</keyword>
  <keyword>sodium thiosulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

